

Glenda Halliday

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7383115/publications.pdf](https://exaly.com/author-pdf/7383115/publications.pdf)

Version: 2024-02-01

677
papers

75,217
citations

650
119
h-index

760
242
g-index

760
all docs

760
docs citations

760
times ranked

46102
citing authors

#	ARTICLE	IF	CITATIONS
1	A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.4	4
2	A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.4	1
3	Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach. <i>Movement Disorders</i> , 2024, 39, 462-471.	4.2	2
4	An attentional and working memory theory of hallucination vulnerability in frontotemporal dementia. <i>Brain Communications</i> , 2024, 6, .	3.3	0
5	Distribution Patterns of Astrocyte Populations in the Human Cortex. <i>Neurochemical Research</i> , 2023, 48, 1222-1232.	3.3	9
6	Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. <i>Brain</i> , 2023, 146, e17-e19.	7.9	2
7	Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy. <i>Cells</i> , 2023, 12, 739.	4.2	6
8	Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	6
9	Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia. <i>Science Advances</i> , 2023, 9, .	10.7	13
10	Effects of STN/SNr deep brain stimulation in a case of progressive supranuclear palsy with a Parkinson disease phenotype. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 821-823.	1.7	0
11	Past antihypertensive medication use is associated with lower levels of small vessel disease and lower A β 2 plaque stage in the brains of older individuals. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	5
12	The importance of patient-centred drug development for amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	0
13	Parkinsonism and cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120011.	0.6	15
14	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of β -Synuclein Autoantibodies in Human Plasma. <i>Bioconjugate Chemistry</i> , 2022, , .	3.7	0
15	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. <i>Neurobiology of Aging</i> , 2022, 112, 122-128.	3.1	4
16	Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. <i>Scientific Reports</i> , 2022, 12, 40.	3.4	9
17	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia. <i>Cortex</i> , 2022, 149, 73-84.	2.6	3
18	Prion-like β -synuclein pathology in the brain of infants with Krabbe disease. <i>Brain</i> , 2022, 145, 1257-1263.	7.9	11

#	ARTICLE	IF	CITATIONS
19	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. <i>NeuroImage: Clinical</i> , 2022, 33, 102958.	2.8	5
20	Examining the presence and nature of delusions in Alzheimer's disease and frontotemporal dementia syndromes. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.6	5
21	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	7.9	25
22	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. <i>Npj Parkinson's Disease</i> , 2022, 8, 16.	5.4	6
23	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. <i>Science Advances</i> , 2022, 8, eabm5386.	10.7	91
24	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. <i>Npj Parkinson's Disease</i> , 2022, 8, 34.	5.4	23
25	Schizotypal traits across the amyotrophic lateral sclerosis–frontotemporal dementia spectrum: pathomechanistic insights. <i>Journal of Neurology</i> , 2022, 269, 4241-4252.	3.7	3
26	Thalamic and Cerebellar Regional Involvement across the ALS–FTD Spectrum and the Effect of C9orf72. <i>Brain Sciences</i> , 2022, 12, 336.	2.3	9
27	Immune responses in the Parkinson's disease brain. <i>Neurobiology of Disease</i> , 2022, 168, 105700.	4.4	35
28	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	4.2	289
29	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. <i>Brain Communications</i> , 2022, 4, .	3.3	4
30	Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. <i>Brain</i> , 2022, 145, 3108-3130.	7.9	36
31	Overlap between Central and Peripheral Transcriptomes in Parkinson's Disease but Not Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5200.	4.1	5
32	Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. <i>Brain</i> , 2022, 145, 3472-3487.	7.9	36
33	An Adaptive Measure of Visuospatial Impairment in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 619-627.	1.7	3
34	A small molecule toll-like receptor antagonist rescues α -synuclein fibril pathology. <i>Journal of Biological Chemistry</i> , 2022, 298, 102260.	3.4	7
35	Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. <i>Brain Communications</i> , 2022, 4, .	3.3	6
36	Prevalence of chronic traumatic encephalopathy in the Sydney Brain Bank. <i>Brain Communications</i> , 2022, 4, .	3.3	16

#	ARTICLE	IF	CITATIONS
37	Common Variants Near <scp>ZIC1</scp> and <scp>ZIC4</scp> in Autopsy-Confirmed Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 2110-2121.	4.2	11
38	The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	8
39	Adaptive structural changes in the motor cortex and white matter in Parkinson's disease. <i>Acta Neuropathologica</i> , 2022, 144, 861-879.	7.8	21
40	Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria. <i>Brain Sciences</i> , 2022, 12, 1594.	2.3	2
41	Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2022, 5, .	3.3	4
42	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 86-95.	5.9	197
43	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. <i>Aging Brain</i> , 2021, 1, 100011.	1.5	2
44	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1743-e1754.	1.3	26
45	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	20.1	229
46	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	9.1	60
47	Globular glial tauopathy with a mutation in MAPT and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. <i>Acta Neuropathologica</i> , 2021, 141, 791-794.	7.8	5
48	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. <i>Scientific Reports</i> , 2021, 11, 4865.	3.4	30
49	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	2.9	67
50	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 979-989.	3.2	35
51	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2085-2093.	4.2	24
52	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	1.3	13
53	Prodromal neuroinvasion of pathological α -synuclein in brainstem reticular nuclei and white matter lesions in a model of α -synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcb104.	3.3	8
54	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2192-2199.	3.5	6

#	ARTICLE	IF	CITATIONS
55	Anterior-posterior electrophysiological activity characterizes Parkinsonian visual misperceptions. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 312-318.	0.4	2
56	Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 6880-6895.	8.0	27
57	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS-FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1576-1591.	3.6	17
58	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	2.9	17
59	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	5.4	83
60	PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612476.	3.7	39
61	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.4	513
62	Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. <i>Analytical Chemistry</i> , 2021, 93, 11108-11115.	6.6	7
63	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 177.	7.3	20
64	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson's Disease Patient Monocytes and Inversely Correlates with Motor Severity. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1157-1165.	2.9	12
65	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. <i>Neurology</i> , 2021, 97, e1031-e1040.	1.3	14
66	Early white matter pathology in the fornix of the limbic system in Huntington disease. <i>Acta Neuropathologica</i> , 2021, 142, 791-806.	7.8	13
67	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. <i>Neurobiology of Disease</i> , 2021, 157, 105426.	4.4	8
68	Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease. <i>Frontiers in Immunology</i> , 2021, 12, 736260.	4.8	2
69	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2021, 107, 11-20.	3.1	1
70	Hypothalamic symptoms of frontotemporal dementia disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 269-280.	0.3	10
71	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	7.8	132
72	The aging brain and brain banking. , 2021, , 103-112.		0

#	ARTICLE	IF	CITATIONS
73	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1153-1161.	2.7	13
74	Tackling clinical heterogeneity across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum using a transdiagnostic approach. <i>Brain Communications</i> , 2021, 3, fcab257.	3.3	19
75	Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. <i>Scientific Reports</i> , 2021, 11, 21348.	3.4	14
76	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. <i>Frontiers in Neurology</i> , 2021, 12, 743688.	2.4	6
77	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. <i>Communications Medicine</i> , 2021, 1, .	4.2	15
78	Presence of coâ€“pathology in sporadic earlyâ€“onset Alzheimer disease versus dominantly inherited Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e055045.	0.7	0
79	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. <i>Brain</i> , 2020, 143, 31-46.	7.9	62
80	Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both A β and tau pathology. <i>Neurobiology of Aging</i> , 2020, 89, 129-131.	3.1	20
81	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 333-339.	2.5	7
82	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. <i>Journal of Sleep Research</i> , 2020, 29, e12939.	3.2	21
83	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. <i>Journal of Neurology</i> , 2020, 267, 380-389.	3.7	21
84	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2020, 105, 201.	7.9	3
85	Are mutations in <i>MAPT</i> associated with GGT type III?. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 406-409.	3.2	4
86	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	196
87	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. <i>Neurobiology of Disease</i> , 2020, 144, 105049.	4.4	11
88	The complex relationship between genotype, pathology and phenotype in familial dementia. <i>Neurobiology of Disease</i> , 2020, 145, 105082.	4.4	9
89	Neuronal intranuclear inclusion disease is genetically heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1716-1725.	3.6	42
90	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	3.4	5

#	ARTICLE	IF	CITATIONS
91	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. <i>Scientific Reports</i> , 2020, 10, 13741.	3.4	32
92	A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1122-1126.	1.7	1
93	Circular RNAs: The Brain Transcriptome Comes Full Circle. <i>Trends in Neurosciences</i> , 2020, 43, 752-766.	8.7	52
94	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12060.	3.8	14
95	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.7	38
96	Alzheimer's amyloid β and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue. <i>Brain and Behavior</i> , 2020, 10, e01672.	2.3	8
97	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 76.	5.3	25
98	The Neural Signature of Impaired Dual-Tasking in Idiopathic Rapid Eye Movement Sleep Behavior Disorder Patients. <i>Movement Disorders</i> , 2020, 35, 1596-1606.	4.2	13
99	CYLD is a causative gene for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2020, 143, 783-799.	7.9	66
100	Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 1238.	12.8	94
101	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 162-171.	5.9	9
102	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	6.3	92
103	Accelerated loss of hypoxia response in zebrafish with familial Alzheimer's disease-like mutation of presenilin 1. <i>Human Molecular Genetics</i> , 2020, 29, 2379-2394.	3.0	12
104	Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. <i>Scientific Reports</i> , 2020, 10, 3640.	3.4	40
105	Invited Reply to: Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , 2020, 35, 195-196.	4.2	0
106	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	5.4	40
107	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. <i>Acta Neuropathologica</i> , 2020, 139, 717-734.	7.8	16
108	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	5.3	27

#	ARTICLE	IF	CITATIONS
109	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease?. <i>Brain</i> , 2020, 143, 3518-3521.	7.9	3
110	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. <i>Bio-protocol</i> , 2020, 10, e3572.	0.4	3
111	<i>SIRT1</i> is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 361-379.	3.2	33
112	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	7.8	17
113	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	3.4	11
114	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	7.9	13
115	Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	3.4	82
116	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	7.9	47
117	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	9.9	174
118	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	4.1	184
119	Parkinson's progression prediction using machine learning and serum cytokines. <i>Npj Parkinson's Disease</i> , 2019, 5, 14.	5.4	68
120	Cross-examining candidate genes implicated in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 117.	5.3	23
121	Chronic traumatic encephalopathy in two former Australian National Rugby League players. <i>Acta Neuropathologica Communications</i> , 2019, 7, 97.	5.3	30
122	Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 130, 104524.	4.4	21
123	TDP-43 levels in the brain tissue of ALS cases with and without <i>C9ORF72</i> or <i>ATXN2</i> gene expansions. <i>Neurology</i> , 2019, 93, e1748-e1755.	1.3	21
124	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,596
125	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. <i>Genome Medicine</i> , 2019, 11, 54.	8.4	223
126	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA ^{A53T}) mouse lines. <i>Acta Neuropathologica</i> , 2019, 137, 437-454.	7.8	67

#	ARTICLE	IF	CITATIONS
127	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 486-495.	3.6	41
128	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	7.8	52
129	Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2019, 34, 1374-1380.	4.2	40
130	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 605-614.	1.7	21
131	Targeted, High-Resolution RNA Sequencing of Non-coding Genomic Regions Associated With Neuropsychiatric Functions. <i>Frontiers in Genetics</i> , 2019, 10, 309.	2.3	31
132	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 963-967.	2.7	10
133	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e2472-e2482.	1.3	16
134	Temporal evolution of microglia and α -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700.	7.9	79
135	β 2 and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. <i>Science Translational Medicine</i> , 2019, 11, .	13.2	106
136	Impaired Color Discrimination—A Specific Marker of Hallucinations in Lewy Body Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 257-264.	2.5	12
137	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	7.9	956
138	Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. <i>Brain Pathology</i> , 2019, 29, 813-825.	4.1	26
139	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	4.2	81
140	Dopamine depletion alters macroscopic network dynamics in Parkinson's disease. <i>Brain</i> , 2019, 142, 1024-1034.	7.9	55
141	The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 310-316.	2.1	16
142	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.4	29
143	Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.8	96
144	The underacknowledged PPA-ALS. <i>Neurology</i> , 2019, 92, e1354-e1366.	1.3	33

#	ARTICLE	IF	CITATIONS
145	Heritability in frontotemporal tauopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	2.5	18
146	Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain. <i>Frontiers in Neuroscience</i> , 2019, 13, 1187.	2.9	15
147	Structural heterogeneity of $\hat{1}\pm$ -synuclein fibrils amplified from patient brain extracts. <i>Nature Communications</i> , 2019, 10, 5535.	12.8	166
148	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 195.	5.3	21
149	LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 406-415.	4.2	85
150	Predictors of survival and progression in behavioural variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2019, 26, 774-779.	3.5	23
151	Apolipoprotein D Upregulation in Alzheimer's Disease but Not Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 125-132.	2.4	30
152	Brain Banking for Research into Neurodegenerative Disorders and Ageing. <i>Neuroscience Bulletin</i> , 2019, 35, 283-288.	3.4	14
153	Gut-brain axis and the spread of $\hat{1}\pm$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	4.2	150
154	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	23.0	179
155	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.1	13
156	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <i>Neuroscience</i> , 2018, 374, 326-334.	2.4	29
157	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. <i>Brain</i> , 2018, 141, 486-495.	7.9	38
158	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	7.9	120
159	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	4.5	95
160	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. <i>American Journal of Pathology</i> , 2018, 188, 1447-1456.	4.0	8
161	Physiological changes in neurodegeneration - mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	9.9	73
162	Accumulation of dysfunctional SOD1 protein in Parkinson's disease is not associated with mutations in the SOD1 gene. <i>Acta Neuropathologica</i> , 2018, 135, 155-156.	7.8	24

#	ARTICLE	IF	CITATIONS
163	MSA prions exhibit remarkable stability and resistance to inactivation. <i>Acta Neuropathologica</i> , 2018, 135, 49-63.	7.8	76
164	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.3	27
165	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	10.2	205
166	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 522-532.	3.2	10
167	P1â€405: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. <i>Alzheimer's and Dementia</i> , 2018, 14, P459.	0.7	0
168	A52â€...SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, , .	5.9	0
169	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2018, 12, 847.	2.9	18
170	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. <i>ENeuro</i> , 2018, 5, ENEURO.0234-18.2018.	1.9	12
171	LRP10 in Î±-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	10.2	13
172	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	7.9	44
173	Psychiatric disorders in <i>C9orf72</i> kindreds. <i>Neurology</i> , 2018, 91, e1498-e1507.	1.3	80
174	Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. <i>Frontiers in Psychology</i> , 2018, 9, 1615.	2.2	9
175	Reply: Will FTLD-tau work for all when FTDP-17 retires?. <i>Brain</i> , 2018, 141, e63-e63.	7.9	3
176	Reduced glucocerebrosidase activity in monocytes from patients with Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2018, 8, 15446.	3.4	86
177	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinsonâ€™s disease. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 70-74.	1.5	19
178	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. <i>Neurobiology of Disease</i> , 2018, 120, 76-87.	4.4	16
179	Lipidomics Analysis of Behavioral Variant Frontotemporal Dementia: A Scope for Biomarker Development. <i>Frontiers in Neurology</i> , 2018, 9, 104.	2.4	37
180	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	4.2	120

#	ARTICLE	IF	CITATIONS
181	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	4.2	188
182	Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. <i>Translational Psychiatry</i> , 2017, 7, e1003-e1003.	4.9	63
183	Selective neuronal vulnerability in Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 101-113.	10.5	764
184	ALS/FTLD: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 177-196.	7.8	81
185	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	6.5	27
186	Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model. <i>Aging Cell</i> , 2017, 16, 377-386.	6.7	29
187	Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 163-170.	2.7	18
188	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 701-709.	2.7	30
189	The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias. <i>European Journal of Neurology</i> , 2017, 24, 956-965.	3.5	11
190	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	5.7	74
191	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients". <i>British Journal of Dermatology</i> , 2017, 176, 552-553.	1.7	2
192	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. <i>Movement Disorders</i> , 2017, 32, 423-432.	4.2	42
193	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. <i>Acta Neuropathologica</i> , 2017, 134, 113-127.	7.8	81
194	Early-life decline in neurogenesis markers and age-related changes of TrkB splice variant expression in the human subependymal zone. <i>European Journal of Neuroscience</i> , 2017, 46, 1768-1778.	3.5	7
195	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.3	2,997
196	Multisite Assessment of Aging-Related Tau Astroglialopathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	1.7	41
197	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. <i>NeuroImage: Clinical</i> , 2017, 13, 439-445.	2.8	65
198	Parkinson's Disease Is Not Simply a Prion Disorder. <i>Journal of Neuroscience</i> , 2017, 37, 9799-9807.	3.7	147

#	ARTICLE	IF	CITATIONS
199	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. <i>Metallomics</i> , 2017, 9, 1447-1455.	2.5	93
200	Pathology and hippocampal atrophy in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2017, 16, 862-864.	10.2	91
201	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	4.2	644
202	Assessment of amyloid β^2 in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	2.5	39
203	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 298, 202-209.	4.1	76
204	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 196-205.	2.5	9
205	Clinical Aspects of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2017, 15, 31-53.	0.0	10
206	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12
207	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. <i>Neurobiology of Disease</i> , 2017, 97, 179-188.	4.4	42
208	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	7.8	212
209	Increased aneuploidy is not a universal feature across α -synucleinopathies. <i>Movement Disorders</i> , 2017, 32, 475-476.	4.2	5
210	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 773-783.	2.7	48
211	[S3 ⁰¹]: MIXED PATHOLOGY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P877.	0.7	0
212	White matter changes in frontotemporal dementia and the C9ORF72 gene expansions. <i>Journal of the Neurological Sciences</i> , 2017, 381, 803.	0.6	0
213	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 705-715.	2.7	21
214	Deletion of Alzheimer's Disease Risk Gene ABCA7 Alters White Adipose Tissue Development and Leptin Levels. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 237-247.	2.2	5
215	β -Synuclein Regulates Neuronal Cholesterol Efflux. <i>Molecules</i> , 2017, 22, 1769.	3.8	32
216	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2017, 5, 76.	5.3	28

#	ARTICLE	IF	CITATIONS
217	Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 274.	3.4	42
218	ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic A β Clearance. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 253.	3.8	23
219	Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157924.	2.5	70
220	Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease. <i>PLoS ONE</i> , 2016, 11, e0160501.	2.5	21
221	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. <i>Movement Disorders</i> , 2016, 31, 889-897.	4.2	76
222	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016, 175, 1073-1075.	1.7	92
223	Neuropathology of α -synuclein propagation and braak hypothesis. <i>Movement Disorders</i> , 2016, 31, 152-160.	4.2	113
224	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. <i>Annals of Neurology</i> , 2016, 79, 295-305.	5.7	31
225	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2016, 175, 1363-1365.	1.7	16
226	Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. <i>Scientific Reports</i> , 2016, 6, 31391.	3.4	34
227	Neuronal network disintegration: common pathways linking neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1234-1241.	5.9	110
228	ABCA7 Mediates Phagocytic Clearance of Amyloid- β in the Brain. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 569-584.	2.7	75
229	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 26697.	3.4	89
230	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.7	100
231	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2016, 366, 197-201.	0.6	10
232	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	93
233	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	11.6	41
234	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	4.2	45

#	ARTICLE	IF	CITATIONS
235	Characterization of circular RNA landscape in multiple system atrophy brain. <i>Journal of Neurochemistry</i> , 2016, 139, 485-496.	4.0	81
236	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.3	84
237	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	2.5	23
238	Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. <i>Journal of Neurology</i> , 2016, 263, 1593-1603.	3.7	52
239	Animal modeling an oligodendroglialopathy in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 12.	5.3	16
240	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. <i>Lancet Neurology</i> , The, 2016, 15, 332-342.	10.2	125
241	Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. <i>Brain</i> , 2016, 139, 845-855.	7.9	111
242	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	81
243	Aging-related tau astroglialopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	7.8	401
244	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 98-107.	2.1	56
245	Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 89-94.	2.2	29
246	Distinctive pathological mechanisms involved in primary progressive Aphasia. <i>Neurobiology of Aging</i> , 2016, 38, 82-92.	3.1	49
247	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. <i>Neurobiology of Learning and Memory</i> , 2016, 130, 34-43.	2.0	24
248	The frontotemporal dementia-motor neuron disease continuum. <i>Lancet</i> , The, 2016, 388, 919-931.	11.9	308
249	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. <i>Neuroscience</i> , 2016, 322, 234-250.	2.4	26
250	Hallucinogenic mechanisms: pathological and pharmacological insights. , 2015, , 119-149.		6
251	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	4.2	1,083
252	Neuropathologic assessment of participants in two multicenter longitudinal observational studies: The Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , 2015, 35, 390-400.	1.2	74

#	ARTICLE	IF	CITATIONS
253	Early disruption of glial communication via connexin gap junction in multiple sclerosis, <sc>B</sc>al's disease and neuromyelitis optica. <i>Neuropathology</i> , 2015, 35, 469-480.	1.2	45
254	The relationships between mild cognitive impairment and phenotype in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2015, 1, 15015.	5.4	21
255	Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. <i>Npj Parkinson's Disease</i> , 2015, 1, 15003.	5.4	78
256	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 175-185.	2.9	16
257	Early in vivo Effects of the Human Mutant Amyloid- β^2 Protein Precursor (hA β^2 PPSwInd) on the Mouse Olfactory Bulb. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 443-457.	2.7	5
258	Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 175-181.	1.7	30
259	Restricted disease propagation in multiple system atrophy with prolonged survival. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 681-685.	3.2	4
260	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 843-848.	3.2	31
261	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1639-1647.	4.2	132
262	Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2015, 30, 796-804.	4.2	37
263	Terra incognita—cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 121.	3.4	23
264	SNCAGene, but NotMAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	17
265	Aneuploidy in Lewy body diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1253-1260.	3.1	23
266	Progressive supranuclear palsy finally has a clinically measurable Δ abnormality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 241-241.	5.9	0
267	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	4.2	4,805
268	F2-03-04: Genetic risk factors for posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2015, 11, P168-P169.	0.7	2
269	Unusual β -synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without <sc>i>SGCE</sc> mutation. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 837-842.	3.2	1
270	PART is part of Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 749-756.	7.8	267

#	ARTICLE	IF	CITATIONS
271	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. <i>Brain</i> , 2015, 138, 3110-3122.	7.9	95
272	Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement: Figure 1. <i>Brain</i> , 2015, 138, 2116-2119.	7.9	22
273	Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. <i>Neurogenetics</i> , 2015, 16, 107-122.	1.5	35
274	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. <i>Neurogenetics</i> , 2015, 16, 201-213.	1.5	19
275	High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. <i>Molecular Brain</i> , 2015, 8, 2.	3.0	26
276	Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 906-925.	3.2	42
277	FTD and ALS—translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	9.9	64
278	Generation and characterization of novel conformation-specific monoclonal antibodies for β -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	4.4	121
279	Protective properties of lysozyme on β -amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015, 83, 122-133.	4.4	59
280	Progression in Behavioral Variant Frontotemporal Dementia. <i>JAMA Neurology</i> , 2015, 72, 1501.	9.1	50
281	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. <i>Acta Neuropathologica Communications</i> , 2015, 3, 47.	5.3	72
282	The Differentiation of Progressive Supranuclear Palsy. <i>Neurodegenerative Disease Management</i> , 2015, 5, 385-388.	2.2	2
283	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). <i>Neurobiology of Disease</i> , 2015, 82, 445-454.	4.4	33
284	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. <i>Acta Neuropathologica</i> , 2015, 130, 661-678.	7.8	62
285	Evidence for β -synuclein prions causing multiple system atrophy in humans with parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5308-17.	7.4	600
286	Is CHCHD10 Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?: Figure 1. <i>Brain</i> , 2015, 138, e385-e385.	7.9	16
287	Eating behavior in frontotemporal dementia. <i>Neurology</i> , 2015, 85, 1310-1317.	1.3	74
288	β -dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. <i>Nature Communications</i> , 2015, 6, 8836.	12.8	71

#	ARTICLE	IF	CITATIONS
289	The role of transcriptional control in multiple system atrophy. <i>Neurobiology of Aging</i> , 2015, 36, 394-400.	3.1	10
290	Reply: Lysosomal dysfunction in Parkinson's disease. <i>Brain</i> , 2015, 138, e340-e340.	7.9	1
291	Inflammation is genetically implicated in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 89-102.	2.4	186
292	Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer's disease. <i>Current Alzheimer Research</i> , 2015, 12, 745-751.	1.5	9
293	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. <i>PLoS ONE</i> , 2014, 9, e87119.	2.5	29
294	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. <i>PLoS ONE</i> , 2014, 9, e105632.	2.5	81
295	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 57.	2.9	74
296	Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. , 2014, , 15.		0
297	Exploring Myelin Dysfunction in Multiple System Atrophy. <i>Experimental Neurobiology</i> , 2014, 23, 337-344.	1.6	36
298	ABCA5 Regulates Amyloid- β Peptide Production and is Associated with Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 857-869.	2.7	42
299	Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 150.	5.3	65
300	Alpha-synuclein biology in Lewy body diseases. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 73.	6.3	307
301	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	3.0	186
302	DNA methylation of the <i>MAPT</i> gene in Parkinson's disease cohorts and modulation by vitamin E <i>In Vitro</i> . <i>Movement Disorders</i> , 2014, 29, 1606-1614.	4.2	84
303	Visual hallucinations in Parkinson's disease: Theoretical models. <i>Movement Disorders</i> , 2014, 29, 1591-1598.	4.2	73
304	The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 2206-2219.	3.6	114
305	Systemic metabolism in frontotemporal dementia. <i>Neurology</i> , 2014, 83, 1812-1818.	1.3	48
306	Prodegenerative β -syn expression in oligodendroglial β -synuclein models of multiple system atrophy. <i>Neurobiology of Disease</i> , 2014, 63, 171-183.	4.4	10

#	ARTICLE	IF	CITATIONS
307	c-Abl phosphorylates α -synuclein and regulates its degradation: implication for α -synuclein clearance and contribution to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 2858-2879.	3.0	190
308	Lipid dysfunction and pathogenesis of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 15.	5.3	42
309	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	7.8	128
310	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	4.2	300
311	Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. <i>Brain</i> , 2014, 137, 2065-2076.	7.9	54
312	α -Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	2.2	295
313	Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson's disease. <i>Brain</i> , 2014, 137, 834-848.	7.9	416
314	Copper pathology in vulnerable brain regions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 858-866.	3.1	194
315	Longitudinal white matter changes in frontotemporal dementia subtypes. <i>Human Brain Mapping</i> , 2014, 35, 3547-3557.	3.6	80
316	Glucocerebrosidase deficits in sporadic Parkinson disease. <i>Autophagy</i> , 2014, 10, 1350-1351.	11.5	50
317	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 865-870.	5.9	203
318	Misfolded proteins in Huntington disease fetal grafts: Further evidence of cell-to-cell transfer?. <i>Annals of Neurology</i> , 2014, 76, 20-21.	5.7	2
319	Heritability in frontotemporal dementia: more missing pieces?. <i>Journal of Neurology</i> , 2014, 261, 2170-2177.	3.7	28
320	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. <i>Brain</i> , 2014, 137, 2493-2508.	7.9	240
321	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	5.9	128
322	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	4.2	119
323	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.2	327
324	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	4.2	391

#	ARTICLE	IF	CITATIONS
325	Tricks of the mind: Visual hallucinations as disorders of attention. <i>Progress in Neurobiology</i> , 2014, 116, 58-65.	5.7	161
326	Distribution of Pathology in Frontal Variant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 63-70.	2.7	55
327	P1-039: MAPT METHYLATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2014, 10, P317-P318.	0.7	3
328	DATâ€SPECT diagnoses dopamine depletion, but not PD. <i>Movement Disorders</i> , 2014, 29, 1705-1706.	4.2	16
329	Alpha Synuclein in Parkinsonâ€™s Disease. , 2014, , 691-726.		4
330	The Role of Astrocytes in Parkinsonâ€™s Disease. , 2014, , 127-144.		3
331	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. <i>PLoS ONE</i> , 2014, 9, e102909.	2.5	79
332	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. <i>Movement Disorders</i> , 2013, 28, 1351-1359.	4.2	22
333	Classification of FTL-D-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. <i>Acta Neuropathologica Communications</i> , 2013, 1, 33.	5.3	49
334	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimerâ€™s disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 30.	5.3	18
335	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2013, 1, 11.	5.3	63
336	Pathway Analysis of the Human Brain Transcriptome in Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 28-36.	2.4	17
337	Can we clinically diagnose dementia with Lewy bodies yet?. <i>Translational Neurodegeneration</i> , 2013, 2, 4.	8.1	44
338	Frontotemporal dementiaâ€™amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1â€™q12.2: genetic, clinical and neuropathological analysis. <i>Acta Neuropathologica</i> , 2013, 125, 523-533.	7.8	24
339	Disease duration and the integrity of the nigrostriatal system in Parkinsonâ€™s disease. <i>Brain</i> , 2013, 136, 2419-2431.	7.9	1,024
340	Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1804-1806.	4.2	2
341	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 873-886.	3.1	45
342	Motor deficits associated with changes in AÎ-amyloid in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 475-476.	5.9	1

#	ARTICLE	IF	CITATIONS
343	An Improved High-Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. <i>Lipids</i> , 2013, 48, 307-318.	1.7	78
344	DNA extraction from fresh-frozen and formalin-fixed, paraffin-embedded human brain tissue. <i>Neuroscience Bulletin</i> , 2013, 29, 649-654.	3.4	26
345	Mutations in protein N-arginine methyltransferases are not the cause of FTL-D-FUS. <i>Neurobiology of Aging</i> , 2013, 34, 2235.e11-2235.e13.	3.1	13
346	Unlocking the Secrets of Lrrk2 Function With Selective Kinase Inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.5	4
347	Localization of copper and copper transporters in the human brain. <i>Metallomics</i> , 2013, 5, 43-51.	2.5	127
348	Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels <i>in vitro</i> and treatment of the A315T-TARDBP mouse model. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1198-204.	2.4	10
349	Tenuigenin Attenuates α -Synuclein-Induced Cytotoxicity by Down-Regulating Polo-Like Kinase 3. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 688-694.	4.0	15
350	Increased Expression of ABCA8 in Multiple System Atrophy Brain is Associated with Changes in Pathogenic Proteins. <i>Journal of Parkinson's Disease</i> , 2013, 3, 331-339.	2.9	19
351	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	9.1	392
352	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2013, 3, 145-152.	2.9	44
353	FAS-Dependent Cell Death in α -Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e55243.	2.5	28
354	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. <i>PLoS ONE</i> , 2013, 8, e74016.	2.5	17
355	Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. <i>PLoS ONE</i> , 2013, 8, e78480.	2.5	42
356	C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. <i>Neurology</i> , 2012, 79, 995-1001.	1.3	109
357	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2012, 135, 3015-3025.	7.9	159
358	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 35-39.	2.7	22
359	Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2012, 167, 631-636.	1.7	25
360	Srp20 regulates TrkB pre-mRNA splicing to generate TrkB ^{Shc} transcripts with implications for Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 123, 159-171.	4.0	30

#	ARTICLE	IF	CITATIONS
361	An evidence base for noradrenergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1589-1591.	4.2	7
362	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. <i>Acta Neuropathologica</i> , 2012, 124, 373-382.	7.8	94
363	Changes in Sphingomyelin Level Affect Alpha-Synuclein and ABCA5 Expression. <i>Journal of Parkinson's Disease</i> , 2012, 2, 41-46.	2.9	30
364	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. <i>Neuroscience</i> , 2012, 210, 363-374.	2.4	34
365	Role of hippocalcin in mediating A β toxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1247-1257.	3.7	12
366	Small vessel disease in patients with Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2012, 27, 1506-1512.	4.2	49
367	Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. <i>Biological Psychiatry</i> , 2012, 71, 783-791.	1.3	86
368	Reduced T helper and B lymphocytes in Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2012, 252, 95-99.	2.4	166
369	An emerging role for LRRK2 in the immune system. <i>Biochemical Society Transactions</i> , 2012, 40, 1134-1139.	3.4	36
370	Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. , 2012, , 439-455.		24
371	Aspects of Innate Immunity and Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2012, 3, 33.	3.6	17
372	A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. <i>Brain Structure and Function</i> , 2012, 217, 591-612.	2.3	147
373	Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1004-1011.	4.2	14
374	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1262-1267.	4.2	46
375	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 673-686.	2.8	66
376	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. <i>Journal of Comparative Neurology</i> , 2012, 520, 2591-2607.	1.9	83
377	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α -synuclein mutation. <i>Translational Neurodegeneration</i> , 2012, 1, 2.	8.1	25
378	The relationship between clinical and pathological variables in Richardson's syndrome. <i>Journal of Neurology</i> , 2012, 259, 482-490.	3.7	19

#	ARTICLE	IF	CITATIONS
379	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1033-1037.	5.9	153
380	Isoform-specific proteolysis of apolipoprotein-E in the brain. <i>Neurobiology of Aging</i> , 2011, 32, 257-271.	3.1	49
381	Interaction between α -Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 271-276.	2.9	15
382	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2011, 8, 765-770.	1.5	49
383	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. <i>Pathology</i> , 2011, 43, 93-102.	0.7	8
384	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.7	93
385	Changes in the solubility and phosphorylation of α -synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	7.8	111
386	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	7.8	366
387	Striatal β -amyloid in dementia with Lewy bodies but not Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 713-719.	2.8	83
388	Pathological Staging of Frontotemporal Lobar Degeneration. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 379-383.	2.4	26
389	Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 256-263.	4.2	43
390	Glia: Initiators and progressors of pathology in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 6-17.	4.2	388
391	Milestones in Parkinson's disease—Clinical and pathologic features. <i>Movement Disorders</i> , 2011, 26, 1015-1021.	4.2	153
392	Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?. <i>Movement Disorders</i> , 2011, 26, 2154-2159.	4.2	169
393	Eating and hypothalamus changes in behavioral variant frontotemporal dementia. <i>Annals of Neurology</i> , 2011, 69, 312-319.	5.7	163
394	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.5	109
395	Clinical phenotypes in autopsy-confirmed Pick disease. <i>Neurology</i> , 2011, 76, 253-259.	1.3	45
396	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. <i>PLoS ONE</i> , 2011, 6, e17299.	2.5	150

#	ARTICLE	IF	CITATIONS
397	Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 981-984.	2.7	54
398	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. <i>Acta Neuropathologica</i> , 2010, 119, 1-4.	7.8	880
399	Focal demyelination in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica</i> , 2010, 119, 567-577.	7.8	159
400	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41.	7.8	226
401	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. <i>Acta Neuropathologica</i> , 2010, 120, 777-788.	7.8	95
402	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. <i>BMC Neuroscience</i> , 2010, 11, 23.	1.8	25
403	Pigmentation in the human brain and risk of Parkinson's disease. <i>Annals of Neurology</i> , 2010, 67, 553-554.	5.7	4
404	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration—motor neuron disease. <i>Annals of Neurology</i> , 2010, 68, 639-649.	5.7	169
405	Effect of age on proliferation-regulating factors in human adult neurogenic regions. <i>Journal of Neurochemistry</i> , 2010, 115, 956-964.	4.0	24
406	Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 312-319.	3.2	72
407	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	20.1	501
408	Missing pieces in the Parkinson's disease puzzle. <i>Nature Medicine</i> , 2010, 16, 653-661.	29.5	632
409	Reply to: "Being too inclusive about synuclein inclusions". <i>Nature Medicine</i> , 2010, 16, 961-961.	29.5	0
410	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 193-205.	2.7	39
411	Pathology of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 132-154.	0.0	6
412	The case of a 48 year-old woman with bizarre and complex delusions. <i>Nature Reviews Neurology</i> , 2010, 6, 175-179.	9.9	25
413	Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. <i>Brain</i> , 2010, 133, e158-e158.	7.9	13
414	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 831-838.	2.5	32

#	ARTICLE	IF	CITATIONS
415	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. <i>Progress in Neurobiology</i> , 2010, 92, 316-329.	5.7	109
416	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	10.2	766
417	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. <i>Movement Disorders</i> , 2009, 24, 833-838.	4.2	56
418	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. <i>Movement Disorders</i> , 2009, 24, 290-292.	4.2	24
419	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1519-1523.	4.2	72
420	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. <i>Movement Disorders</i> , 2009, 24, 2128-2135.	4.2	13
421	Phosphorylation of soluble tau differs in Pickâ€™s disease and Alzheimerâ€™s disease brains. <i>Journal of Neural Transmission</i> , 2009, 116, 1243-1251.	2.8	35
422	Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2009, 117, 19-29.	7.8	26
423	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. <i>Acta Neuropathologica</i> , 2009, 117, 15-18.	7.8	388
424	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 329-337.	3.2	98
425	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2009, 161, 1357-1364.	1.7	81
426	Monocyte Chemoattractant Proteinâ€1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease. <i>Brain Pathology</i> , 2009, 19, 392-398.	4.1	213
427	Tryptophan is a marker of human postmortem brain tissue quality. <i>Journal of Neurochemistry</i> , 2009, 110, 1400-1408.	4.0	13
428	Intralaminar nuclei of the thalamus in Lewy body diseases. <i>Brain Research Bulletin</i> , 2009, 78, 97-104.	3.0	52
429	Anti-melanin antibodies are increased in sera in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 217, 297-301.	4.1	75
430	White matter loss in healthy ageing: A postmortem analysis. <i>Neurobiology of Aging</i> , 2009, 30, 1288-1295.	3.1	68
431	The neural basis of semantic memory: Evidence from semantic dementia. <i>Neurobiology of Aging</i> , 2009, 30, 2043-2052.	3.1	48
432	O.064 Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S17.	2.2	0

#	ARTICLE	IF	CITATIONS
433	P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S164.	2.2	0
434	Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S152-S155.	2.2	137
435	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 688-695.	1.1	16
436	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	1.7	179
437	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Journal of Neurochemistry</i> , 2008, 104, 573-583.	4.0	58
438	The comparative biology of neuromelanin and lipofuscin in the human brain. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1669-1682.	5.4	169
439	The progression of pathology in longitudinally followed patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 409-415.	7.8	347
440	Clarifying the pathological progression of Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 377-378.	7.8	10
441	Excessive dopamine neuron loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2008, 23, 607-610.	4.2	27
442	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. <i>Movement Disorders</i> , 2008, 23, 837-844.	4.2	1,842
443	Haplotype analysis of the IGF2 gene cluster in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 495-499.	1.8	17
444	Pedigree with frontotemporal lobar degeneration motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. <i>BMC Neurology</i> , 2008, 8, 32.	1.8	71
445	Human-based studies on α -synuclein deposition and relationship to Parkinson's disease symptoms. <i>Experimental Neurology</i> , 2008, 209, 12-21.	4.1	40
446	Neuropathologic correlates of white matter hyperintensities. <i>Neurology</i> , 2008, 71, 804-811.	1.3	302
447	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2007, 66, 251-257.	1.7	106
448	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2007, 66, 329-336.	1.7	42
449	VISA: A pass to innate immunity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 287-291.	2.8	18
450	Tau isoform expression in frontotemporal dementia without tau deposition. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1182-1185.	1.5	7

#	ARTICLE	IF	CITATIONS
451	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 414, 170-173.	2.1	9
452	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. <i>NeuroImage</i> , 2007, 34, 1054-1059.	4.3	67
453	p25 [±] Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy. <i>American Journal of Pathology</i> , 2007, 171, 1291-1303.	4.0	171
454	Clinicopathological aspects of motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S208-S210.	2.2	7
455	ORGANIZATION: PYRAMIDAL AND EXTRAPYRAMIDAL SYSTEM. , 2007, , 396-401.		0
456	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. <i>Movement Disorders</i> , 2007, 22, 982-989.	4.2	34
457	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 328-333.	3.2	12
458	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitinâ€“proteasomal system and is present in the pathological features of parkinsonian diseases. <i>Neurobiology of Disease</i> , 2007, 27, 238-247.	4.4	32
459	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 5-22.	7.8	998
460	Lipid content determines aggregation of neuromelanin granules in vitro. , 2007, , 35-38.		5
461	Physiologic and Neurotoxic Properties of AÎ² Peptides. , 2007, , 179-197.		0
462	New face of neuromelanin. , 2006, , 119-123.		26
463	Antigen-Epitope Retrieval To Facilitate Proteomic Analysis of Formalin-Fixed Archival Brain Tissue. <i>Analytical Chemistry</i> , 2006, 78, 7216-7221.	6.6	26
464	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 309-313.	2.2	3
465	Evidence for specific phases in the development of human neuromelanin. <i>Neurobiology of Aging</i> , 2006, 27, 506-512.	3.1	59
466	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 387-393.	3.1	32
467	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1554-1563.	3.1	151
468	Neuropathology in the S305S tau gene mutation. <i>Brain</i> , 2006, 129, E40-E40.	7.9	17

#	ARTICLE	IF	CITATIONS
469	Î²-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <i>Proteomics</i> , 2006, 6, 6566-6577.	3.0	63
470	Cognitive, Extrapyramidal, and Magnetic Resonance Imaging Predictors of Functional Impairment in Nondemented Older Community Dwellers: The Sydney Older Person Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 3-10.	2.9	31
471	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 154, 72-78.	1.7	58
472	Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. <i>British Journal of Dermatology</i> , 2006, 155, 408-415.	1.7	38
473	Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 83-91.	3.2	27
474	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 374-387.	3.2	35
475	Evidence for specific phases in the development of human neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 721-728.	2.8	36
476	Investigation of the lipid component of neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 735-739.	2.8	10
477	P25Î± immunoreactive but Î±-synuclein immunonegative neuronal inclusions in multiple system atrophy. <i>Acta Neuropathologica</i> , 2006, 111, 193-195.	7.8	26
478	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. <i>Acta Neuropathologica</i> , 2006, 111, 329-340.	7.8	98
479	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 171-179.	2.6	31
480	Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 632-638.	4.2	54
481	Mutations in progranulin explain atypical phenotypes with variants in MAPT. <i>Brain</i> , 2006, 129, 3124-3126.	7.9	91
482	Progression in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2006, 63, 1627.	4.5	192
483	Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. <i>Neurocase</i> , 2006, 12, 81-90.	0.7	4
484	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. , 2006, , 99-103.		79
485	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2005, 65, 1863-1872.	1.3	4,671
486	Dolichol is the major lipid component of human substantia nigra neuromelanin. <i>Journal of Neurochemistry</i> , 2005, 92, 990-995.	4.0	61

#	ARTICLE	IF	CITATIONS
487	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. <i>Journal of Neurochemistry</i> , 2005, 95, 599-608.	4.0	29
488	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 503-511.	3.2	19
489	Clarifying Lewy-body parkinsonism with visual hallucinations. <i>Lancet Neurology</i> , The, 2005, 4, 588-589.	10.2	3
490	Pick bodies in a family with presenilin-1 Alzheimer's disease. <i>Annals of Neurology</i> , 2005, 57, 139-143.	5.7	61
491	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. <i>Annals of Neurology</i> , 2005, 58, 829-839.	5.7	193
492	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, 34-39.	4.2	22
493	What is the dominant α^2 species in human brain tissue? A review. <i>Neurotoxicity Research</i> , 2005, 7, 29-41.	2.7	42
494	Insoluble α -synuclein in alzheimer's disease without lewy body formation. <i>Neurotoxicity Research</i> , 2005, 7, 69-76.	2.7	10
495	The emergence of proto-objects in complex visual hallucinations. <i>Behavioral and Brain Sciences</i> , 2005, 28, 767-768.	0.7	2
496	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2005, 128, 2272-2280.	7.9	101
497	The pathological basis of semantic dementia. <i>Brain</i> , 2005, 128, 1984-1995.	7.9	313
498	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. <i>Brain</i> , 2005, 128, 2665-2674.	7.9	320
499	Pathologically proven frontotemporal dementia presenting with severe amnesia. <i>Brain</i> , 2005, 128, 597-605.	7.9	168
500	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. <i>Brain</i> , 2005, 128, 1259-1266.	7.9	135
501	α -Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. <i>Brain</i> , 2005, 128, 2654-2664.	7.9	192
502	Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. <i>Biochemistry</i> , 2005, 44, 7346-7353.	2.6	28
503	Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. <i>Progress in Neurobiology</i> , 2005, 75, 109-124.	5.7	319
504	Localization of immunoreactivity for Deleted in Colorectal Cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. <i>Neuroscience</i> , 2005, 131, 671-681.	2.4	73

#	ARTICLE	IF	CITATIONS
505	Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2005, 232, 83-90.	0.6	80
506	Variable Phenotype of Alzheimer's Disease with Spastic Paraparesis. Research and Perspectives in Alzheimer's Disease, 2005, , 73-92.	0.0	1
507	Thalamic and Cortical Changes in Parkinsonian Disorders. , 2005, , 415-424.		0
508	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		22
509	Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain, 2004, 127, 2214-2220.	7.9	94
510	The Serotonin and Tachykinin Systems. , 2004, , 1205-1256.		10
511	Substantia Nigra and Locus Coeruleus. , 2004, , 449-463.		23
512	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 137-145.	2.5	181
513	Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. British Journal of Dermatology, 2004, 151, 42-49.	1.7	18
514	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathologica, 2004, 108, 515-523.	7.8	107
515	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. Journal of Neurology, 2004, 251, 1098-104.	3.7	43
516	Identification of families with cortical Lewy body disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2004, 128B, 118-122.	1.8	13
517	Clinicopathological correlates in frontotemporal dementia. Annals of Neurology, 2004, 56, 399-406.	5.7	555
518	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. Movement Disorders, 2004, 19, 709-711.	4.2	12
519	Genetic contributions to Parkinson's disease. Brain Research Reviews, 2004, 46, 44-70.	9.0	83
520	A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism and Related Disorders, 2004, 10, 191-202.	2.2	50
521	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiology of Disease, 2004, 15, 115-119.	4.4	33
522	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neuroscience Letters, 2004, 361, 9-12.	2.1	53

#	ARTICLE	IF	CITATIONS
523	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. <i>Neurology</i> , 2004, 63, 1613-1617.	1.3	36
524	The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. <i>Experimental Neurology</i> , 2003, 184, 530-535.	4.1	31
525	Identifying severely atrophic cortical subregions in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 797-806.	3.1	61
526	Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. <i>Behavioural Brain Research</i> , 2003, 139, 105-113.	2.3	59
527	The left human speech-processing cortex is thinner but longer than the right. <i>Laterality</i> , 2003, 8, 247-260.	1.0	59
528	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. <i>Archives of Neurology</i> , 2003, 60, 545.	4.5	177
529	Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy. <i>Journal of Biological Chemistry</i> , 2003, 278, 6748-6754.	3.4	54
530	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. <i>Brain</i> , 2003, 126, 814-826.	7.9	115
531	Survival in frontotemporal dementia. <i>Neurology</i> , 2003, 61, 349-354.	1.3	362
532	Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. <i>Brain</i> , 2003, 126, 827-840.	7.9	78
533	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. <i>Neurology</i> , 2003, 60, 1005-1011.	1.3	248
534	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 747-751.	5.9	120
535	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. <i>Brain</i> , 2002, 125, 391-403.	7.9	592
536	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2431-2445.	7.9	394
537	Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 601-604.	1.2	31
538	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Neurobiology of Disease</i> , 2002, 9, 249-257.	4.4	37
539	Pyramidal Cell Loss in Motor Cortices in Huntington's Disease. <i>Neurobiology of Disease</i> , 2002, 10, 378-386.	4.4	106
540	An inflammatory review of Parkinson's disease. <i>Progress in Neurobiology</i> , 2002, 68, 325-340.	5.7	302

#	ARTICLE	IF	CITATIONS
541	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	7.9	126
542	Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1166-1173.	4.2	114
543	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 133-137.	4.2	93
544	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. <i>Acta Neuropathologica</i> , 2002, 103, 370-376.	7.8	162
545	Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. <i>Acta Neuropathologica</i> , 2002, 104, 72-78.	7.8	54
546	Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. <i>British Journal of Dermatology</i> , 2002, 146, 810-815.	1.7	108
547	Selective hippocampal neuron loss in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2002, 51, 125-128.	5.7	54
548	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	7.9	24
549	Which Basal Ganglia Surgical Targets Ameliorate Parkinsonian Symptoms?. <i>Advances in Behavioral Biology</i> , 2002, , 533-542.	0.0	0
550	Neurofilament-Immunoreactive Neurons Are Not Selectively Vulnerable in Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 136-146.	4.4	8
551	Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 101, 616-624.	7.8	48
552	Cortical Lewy body pathology in the diagnosis of dementia. <i>Acta Neuropathologica</i> , 2001, 102, 355-363.	7.8	266
553	Parkinson's disease with late Pick's dementia. <i>Movement Disorders</i> , 2001, 16, 311-319.	4.2	12
554	Corticobasal syndrome with tau pathology. <i>Movement Disorders</i> , 2001, 16, 656-667.	4.2	62
555	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.7	635
556	Severe Anterograde Amnesia with Extensive Hippocampal Degeneration in a Case of Rapidly Progressive Frontotemporal Dementia.. <i>Neurocase</i> , 2001, 7, 57-64.	0.7	24
557	Alzheimer's disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	1.8	17
558	Cortical degeneration associated with phonologic and semantic language impairments in AD. <i>Neurology</i> , 2001, 56, 944-950.	1.3	39

#	ARTICLE	IF	CITATIONS
559	Transforming growth factor- β 2 produced by regressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. <i>International Immunology</i> , 2001, 13, 1147-1154.	4.0	59
560	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.7	6
561	A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. <i>Brain</i> , 2000, 123, 724-732.	7.9	41
562	Degeneration of the centric $\frac{1}{2}$ median-parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-352.	5.7	170
563	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	5.7	117
564	Topical Retinoic Acid Enhances, and a Dark Tan Protects, from Subedermal Solar-Simulated Photocarcinogenesis. <i>Journal of Investigative Dermatology</i> , 2000, 114, 923-927.	0.7	36
565	Cytokine profiles in spontaneously regressing basal cell carcinomas. <i>British Journal of Dermatology</i> , 2000, 143, 91-98.	1.7	85
566	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 1-8.	1.9	181
567	Practical measures to simplify the Braak tangle staging method for routine pathological screening. <i>Acta Neuropathologica</i> , 2000, 99, 199-208.	7.8	42
568	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. <i>Brain</i> , 2000, 123, 880-893.	7.9	280
569	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2000, 57, 817.	4.5	67
570	Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses. <i>Archives of Neurology</i> , 2000, 57, 1586-91.	4.5	146
571	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 831.	4.5	69
572	Idiopathic generalized epilepsy. <i>Neurology</i> , 2000, 55, 1101-1106.	1.3	58
573	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. <i>Brain</i> , 2000, 123, 1410-1421.	7.9	220
574	Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. <i>Life Sciences</i> , 2000, 66, 1345-1350.	4.3	10
575	Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. <i>Brain</i> , 2000, 123, 141-154.	7.9	355
576	Degeneration of the centric $\frac{1}{2}$ median α -parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-352.	5.7	6

#	ARTICLE	IF	CITATIONS
577	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718.	5.7	1
578	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	5.7	4
579	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. <i>Brain</i> , 1999, 122, 675-686.	7.9	89
580	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 1999, 14, 626-633.	4.2	35
581	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 149-154.	1.5	3
582	Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. <i>Neuroscience</i> , 1999, 91, 429-438.	2.4	171
583	Brain shrinkage in alcoholics: a decade on and what have we learned?. <i>Progress in Neurobiology</i> , 1999, 58, 381-387.	5.7	176
584	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Experimental Neurology</i> , 1999, 158, 135-142.	4.1	38
585	Clinical and Neuropathological Abnormalities in Baboons Treated with HPTP, the Tetrahydropyridine Analog of Haloperidol. <i>Experimental Neurology</i> , 1999, 158, 155-163.	4.1	18
586	Sunscreens and vitamin E provide some protection to the skin immune system from solar-simulated UV radiation. <i>Australasian Journal of Dermatology</i> , 1998, 39, 71-75.	0.8	5
587	Simplified neuropathological diagnosis of dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 195-201.	3.2	39
588	Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. <i>Neurobiology of Aging</i> , 1998, 19, 297-306.	3.1	53
589	The midbrain dopaminergic cell groups in the baboon <i>papio ursinus</i> . <i>Brain Research Bulletin</i> , 1998, 47, 611-623.	3.0	17
590	Regional Specificity of Brain Atrophy in Huntington's Disease. <i>Experimental Neurology</i> , 1998, 154, 663-672.	4.1	226
591	Variation in hippocampal neuron number with age and brain volume. <i>Cerebral Cortex</i> , 1998, 8, 710-718.	3.1	98
592	Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. <i>NeuroReport</i> , 1998, 9, 3335-3339.	1.2	70
593	The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 315-320.	5.9	41
594	Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 51-60.	5.9	389

#	ARTICLE	IF	CITATIONS
595	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 27-35.	2.7	7
596	Language-Associated Cortical Regions Are Proportionally Larger in the Female Brain. Archives of Neurology, 1997, 54, 171-176.	4.5	225
597	The Subthalamic Nucleus in Parkinson's Disease and Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 1997, 56, 132-142.	1.7	61
598	Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata. Experimental Neurology, 1997, 144, 183-192.	4.1	58
599	Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease. Experimental Neurology, 1997, 144, 202-213.	4.1	118
600	Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neuroscience Letters, 1997, 227, 49-52.	2.1	27
601	Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience, 1997, 78, 641-652.	2.4	60
602	The cerebral cortex is damaged in chronic alcoholics. Neuroscience, 1997, 79, 983-998.	2.4	487
603	Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathology and Applied Neurobiology, 1997, 23, 492-495.	3.2	51
604	Prediction of minimal erythema dose with a reflectance melanin meter. British Journal of Dermatology, 1997, 136, 714-718.	1.7	9
605	Chronic alcohol consumption does not cause hippocampal neuron loss in humans. Hippocampus, 1997, 7, 78-87.	2.1	151
606	Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiology of Aging, 1996, 17, 513-521.	3.1	171
607	Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. Neuroscience Letters, 1996, 209, 29-32.	2.1	48
608	Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience, 1996, 72, 699-708.	2.4	139
609	Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease. Experimental Neurology, 1996, 5, 49-55.	1.6	56
610	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. Experimental Neurology, 1996, 5, 177-187.	1.6	19
611	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. Journal of Clinical Neuroscience, 1996, 3, 52-60.	1.5	95
612	Quantification of cortical atrophy in a case of progressive fluent aphasia. Brain, 1996, 119, 181-190.	7.9	95

#	ARTICLE	IF	CITATIONS
613	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.7	7
614	Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. <i>Metabolic Brain Disease</i> , 1996, 11, 217-227.	2.9	13
615	Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. <i>Journal of Neuroscience Methods</i> , 1996, 64, 83-93.	2.6	11
616	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	3.2	3
617	Chronic Alcoholics without Wernicke-Korsakoff Syndrome or Cirrhosis Do Not Lose Serotonergic Neurons in the Dorsal Raphe Nucleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 61-66.	2.5	30
618	NORADRENERGIC LOCUS COERULEUS NEURONS. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 191-192.	2.5	6
619	Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. <i>Journal of Comparative Neurology</i> , 1996, 364, 121-150.	1.9	166
620	Reproducible sampling regimen for specific cortical regions: application to speech-associated areas. <i>Journal of Neuroscience Methods</i> , 1996, 67, 43-51.	2.6	22
621	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 60, 531-538.	5.9	54
622	Pattern of Midbrain Pathology in Different Parkinsonian Syndromes. <i>Advances in Behavioral Biology</i> , 1996, , 441-444.	0.0	2
623	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	3.2	4
624	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.7	4
625	Brain stem nuclei in sudden infant death syndrome (SIDS): volumes, neuronal numbers and positions. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 262-268.	3.2	12
626	Neurofibrillary tangles in chronic alcoholics. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 312-318.	3.2	42
627	Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4 ⁺ T cells. <i>World Journal of Surgery</i> , 1995, 19, 352-358.	1.4	138
628	Ubiquitin-positive achromatic neurons in corticobasal degeneration. <i>Acta Neuropathologica</i> , 1995, 90, 68-75.	7.8	40
629	Comparison of the Number of Vasopressin-Producing Hypothalamic Neurons in Rats and Humans. <i>Journal of Neuroendocrinology</i> , 1995, 7, 629-636.	2.6	14
630	Serotonin and alcohol-related brain damage. <i>Metabolic Brain Disease</i> , 1995, 10, 25-30.	2.9	28

#	ARTICLE	IF	CITATIONS
631	Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. <i>Metabolic Brain Disease</i> , 1995, 10, 81-91.	2.9	34
632	Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. <i>Neuroscience</i> , 1995, 65, 87-91.	2.4	53
633	Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. <i>Neuroscience</i> , 1995, 68, 539-551.	2.4	54
634	Ascending Noradrenergic and Serotonergic Systems in the Human Brainstem. <i>Advances in Behavioral Biology</i> , 1995, , 155-171.	0.0	2
635	Cytoarchitecture and Chemistry of Midbrain Dopaminergic Cell Groups. <i>Advances in Behavioral Biology</i> , 1995, , 115-127.	0.0	1
636	Ubiquitin-positive achromatic neurons in corticobasal degeneration. <i>Acta Neuropathologica</i> , 1995, 90, 68-75.	7.8	8
637	Neurotransmitter Changes in Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1995, , 199-219.	0.0	5
638	Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System. <i>Advances in Behavioral Biology</i> , 1995, , 129-153.	0.0	0
639	Practical considerations for the use of the optical disector in estimating neuronal number. <i>Journal of Neuroscience Methods</i> , 1994, 51, 83-89.	2.6	82
640	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	7.8	30
641	Regression in basal cell carcinoma: an immunohistochemical analysis. <i>British Journal of Dermatology</i> , 1994, 130, 1-8.	1.7	135
642	Effect of Chronic Alcohol Consumption on the Human Locus Coeruleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 1491-1496.	2.5	26
643	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	7.8	4
644	Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain. <i>Synapse</i> , 1993, 15, 1-16.	1.2	45
645	Carcinogen-Treated Skin Allografts Rejected by T Lymphocytes Specific for Class I but Not Class II MHC Antigens. <i>Cellular Immunology</i> , 1993, 151, 291-299.	3.0	0
646	Thalamic vaciation in acute Wernicke's encephalopathy. <i>Metabolic Brain Disease</i> , 1993, 8, 107-113.	2.9	9
647	Parvalbumin as an anatomical marker for discrete subregions of the ambiguous complex in the rat. <i>Neuroscience Letters</i> , 1993, 160, 101-105.	2.1	77
648	Brainstem Serotonergic Neurons in Chronic Alcoholics With and Without the Memory Impairment of Korsakoff's Psychosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 567-579.	1.7	70

#	ARTICLE	IF	CITATIONS
649	Preliminary Evidence Suggesting Delayed Development in the Hypoglossal and Vagal Nuclei of SIDS Infants: A Necropsy Study. <i>Journal of Child Neurology</i> , 1992, 7, 44-49.	1.7	29
650	A Comparative Study of Avidin-Biotin-Peroxidase Complexes for the Immunohistochemical Detection of Antigens in Neural Tissue. <i>Biotechnic and Histochemistry</i> , 1992, 67, 367-371.	1.4	17
651	Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. <i>Journal of Chemical Neuroanatomy</i> , 1992, 5, 311-313.	2.1	19
652	Rostrocaudal differences in morphology and neurotransmitter content of cells in the subretrofacial vasomotor nucleus. <i>Journal of the Autonomic Nervous System</i> , 1992, 38, 117-137.	2.0	35
653	The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. <i>Brain Research</i> , 1992, 598, 33-37.	2.3	39
654	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. <i>Acta Neuropathologica</i> , 1992, 84, 638-50.	7.8	98
655	Regulation of the Skin Immune System by Retinoids During Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 1992, 99, S83-S86.	0.7	20
656	The dorsal, posterodorsal, and ventral tegmental nuclei: A cyto- and chemoarchitectonic study in the human. <i>Journal of Comparative Neurology</i> , 1992, 318, 117-137.	1.9	21
657	Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. <i>Neuroscience</i> , 1991, 42, 757-775.	2.4	205
658	A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide Y in the ventrolateral medulla of rats, guinea-pigs and cats. <i>Neuroscience</i> , 1991, 43, 531-550.	2.4	47
659	Four groups of tyrosine hydroxylase-immunoreactive neurons in the ventrolateral medulla of rats, guinea-pigs and cats identified on the basis of chemistry, topography and morphology. <i>Neuroscience</i> , 1991, 43, 551-568.	2.4	21
660	Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. <i>Synapse</i> , 1991, 7, 301-320.	1.2	85
661	SUBSTANCE P-CONTAINING NEURONS IN THE MESOPONTINE TEGMENTUM ARE SEVERELY AFFECTED IN PARKINSON'S DISEASE. <i>Brain</i> , 1991, 114, 2253-2267.	7.9	89
662	Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. <i>Annals of Neurology</i> , 1990, 27, 373-385.	5.7	355
663	Cytoarchitecture of the human dorsal raphe nucleus. <i>Journal of Comparative Neurology</i> , 1990, 301, 147-161.	1.9	148
664	Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. <i>Neuroscience</i> , 1990, 39, 81-96.	2.4	41
665	Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. <i>Brain Research</i> , 1990, 510, 104-107.	2.3	329
666	Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity. , 1990, , 149-202.		57

#	ARTICLE	IF	CITATIONS
667	Catecholaminergic Neurons. , 1990, , 1023-1049.		29
668	Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Research Bulletin, 1989, 22, 725-735.	3.0	41
669	Distribution of monoamine-synthesizing neurons in the human medulla oblongata. Journal of Comparative Neurology, 1988, 273, 301-317.	1.9	121
670	Distribution of substance P-like immunoreactive neurons in the human medulla oblongata: Co-localization with monoamine-synthesizing neurons. Synapse, 1988, 2, 353-370.	1.2	60
671	Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. Brain Research, 1988, 461, 75-86.	2.3	42
672	Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. Brain Research Bulletin, 1988, 21, 659-670.	3.0	10
673	The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. Neuroscience, 1988, 26, 179-191.	2.4	53
674	Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Research Reviews, 1987, 12, 117-165.	9.0	888
675	Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. Journal of Comparative Neurology, 1986, 252, 423-445.	1.9	133
676	Electron microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. Journal of Comparative Neurology, 1984, 230, 393-412.	1.9	11
677	Research Priorities on the Role of α -Synuclein in Parkinson's Disease Pathogenesis. Movement Disorders, 0, , .	4.2	0